Additional Listing

RNS Number : 1980C
Dechra Pharmaceuticals PLC
15 October 2020
 

 

 

 

 

15 October 2020

 

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

 

 

Additional Listing

 

 

An application for admission to the Premium Segment of the Official List has been made to the Financial Conduct Authority and the London Stock Exchange for the following:

 

· Additional 50,000 for the existing Save As You Earn block listing; and

· Additional 195,000 for the Long Term Incentive Plan 2017 block listing.

 

These Shares will rank pari passu with the Company's existing shares in issue.  It is expected that admission will become effective on or around 20 October 2020 .

 

For further information, please contact:

Dechra Pharmaceuticals PLC

Melanie Hall, Company Secretary

Telephone number:  +44 (0) 1606 814730

Email: corporate.enquiries@dechra.com  

 

About Dechra

Dechra is a global veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com .

 

Trademarks

Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ALSVELBFBBLXFBK
UK 100

Latest directors dealings